Dr Ketan Kumar

About

Molecular Parasitology | CRISPR Functional Genomics | Host–parasite interactions

Molecular parasitologist with expertise in CRISPR/Cas9-mediated genome editing, functional gene characterization, and transcript-level validation in protozoan parasites. Experienced in integrating bioinformatics analysis with experimental validation to study parasite survival mechanisms. Strong interest in infection biology, transcriptomics, and virulence regulation in eukaryotic pathogens.
Gained international research experience through EMBO and LabEx CeMEB fellowships, working in collaborative research.

"A curious mind is better than a brilliant mind"

Employment

• Birla Institute of Technology and Science - Hyderabad Campus Project Research Scientist-I (Postdoctoral Fellow)
  2026 - Present
• Université de Montpellier LabEx CeMEB International Research Mobility Fellow
  2023 - 2023
• Université de Montpellier EMBO Scientific Exchange Grant Fellow
  2022 - 2022
• University of Delhi Department of Biochemistry Project Fellow
  2017 - 2018
• Nitishwar Mahavidyala Resource person
  2015 - 2017
• Community College, Langat Singh College Guest Faculty (Diploma inHealth Care)
  2014 - 2015

Education

• Central University of Rajasthan PhD
  2021 - 2026

Projects & Funding

Projects & funding information is unavailable.

Publications (6)

• Apoptotic proteins in Leishmania donovani: in silico screening, modeling, and validation by knock-out and gene expression analysis
  Parasite 2025 DOI: 10.1051/parasite/2024081
  +Save
• Multi-pathogen based chimeric vaccine to fight against COVID-19 and concomitant coinfections
  Biotechnology Letters 2023 DOI: 10.1007/s10529-023-03380-0
  +Save
• Translational vaccinomics and structural filtration algorithm to device multiepitope vaccine for catastrophic monkeypox virus
  Computers in Biology and Medicine 2023 DOI: 10.1016/j.compbiomed.2022.106497
  +Save
• Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics
  Molecular Diversity 2022 DOI: 10.1007/s11030-022-10570-x
  +Save
• MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies
  Life Sciences 2022 DOI: 10.1016/j.lfs.2022.120761
  +Save
• High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases
  Molecular Diversity 2022 DOI: 10.1007/s11030-022-10452-2
  +Save